With support from Sanofi and the Juvenile Diabetes Research Foundation, Boston-based Selecta Biosciences has raised $20 million to advance drug candidates for Type 1 diabetes and severe gout.
Of the gout program, CEO Werner Cautreels said in a statement: “SEL-212 is just the beginning for us, as we have identified many biopharmaceuticals, including existing and new classes of biologics such as gene therapy, where the effects of anti-drug antibodies are deleterious.”
The company to date has raised $78.6 million in private equity, from investors like Polaris Venture Partners, Flagship Ventures, OrbiMed Advisors, NanoDimension, Rusnano, I2BF, Eminent Venture Capital and Leukon Investments.
